Myriad Genetics :
MYGN
MYGN
Stock Data
$4.80
$0.05 (1.05%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
DIAGNOSTICS & RESEARCH
Myriad Genetics Inc is a pioneer in genetic testing and precision medicine, offering a wide range of molecular diagnostic tests. These tests are crucial in the fields of oncology, women's health, and pharmacogenomics, helping to assess risks for hereditary cancers and guide therapy decisions for various cancers including breast, ovarian, and prostate. Additionally, Myriad Genetics provides tests for prenatal screening and mental health medication guidance, collaborating with notable institutions like Illumina and Memorial Sloan Kettering Cancer Center. Founded in 1992, the company is based in Salt Lake City, Utah.
All Myriad Genetics Articles
85 Articles